{"url_path":"/sec/cgon/8-k/2026-06-08/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-08","source_url":"https://www.sec.gov/Archives/edgar/data/1991792/0001193125-26-261670-index.html","accession_number":"0001193125-26-261670","cik":"0001991792","ticker":"CGON","issuer_name":"CG Oncology, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1991792/0001193125-26-261670-index.html","primary_entity_key":"0001991792","primary_entity_name":"CG Oncology, Inc."},"word_count":452,"has_tables":true,"body_markdown":"Item 5.07 Submission of Matters to a Vote of Security Holders.\n\nOn June 4, 2026, CG Oncology, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 7, 2026, the record date for the Annual Meeting, 88,009,980 shares of common stock were outstanding and entitled to vote at the Annual Meeting. The following tables set forth the final results of the voting for the matters voted upon at the Annual Meeting. These matters are described in more detail in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 24, 2026 (the “Proxy Statement”).\n\nProposal 1: Election of Directors\n\nThe Company’s stockholders elected the two persons listed below as Class II directors, each to serve until the Company’s 2029 Annual Meeting of Stockholders, and until their successors are duly elected and qualified, or until their earlier death, resignation or removal. The final voting results are as follows:\n\n \n\n \n \n\nShares\nVoted For\n\n \n\nShares\nVoted Withhold\n\n \n\nBroker\nNon-Votes\n\nName of Directors Elected\n \n\n \n\n \n\nChristina Rossi\n \n67,531,501\n \n89,825\n \n16,216,685\n\nVictor Tong, Jr.\n \n62,401,874\n \n5,219,452\n \n16,216,685\n\nProposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm\n\nThe Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows:\n\n \n\nShares\nVoted For\n\n \n\nShares\nVoted Against\n\n \n\nAbstentions\n\n83,711,522\n \n4,103\n \n122,386\n\nProposal 3: Advisory Vote on Executive Compensation\n\nThe Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as described in the Proxy Statement. The final voting results are as follows:\n\n \n\nShares\nVoted For\n\n \n\nShares\nVoted Against\n\n \n\nAbstentions\n\n \n\nBroker Non-Votes\n\n65,894,959\n \n1,603,011\n \n123,356\n \n16,216,685\n\nProposal 4: Advisory Vote on the Frequency of Solicitation of Advisory Stockholder Approval of Executive Compensation\n\nThe Company’s stockholders indicated, on an advisory basis, their preference for the frequency of stockholder advisory votes on the compensation of the Company’s named executive officers. The final voting results are as follows:\n\n \n\n1 Year\n\n \n\n2 Years\n\n \n\n3 Years\n\n \n\nAbstentions\n\n \n\nBroker Non-Votes\n\n66,962,791\n \n4,269\n \n537,270\n \n116,996\n \n16,216,685\n\nConsistent with these results, the Company determined that future stockholder advisory votes on named executive officer compensation will be held every year until the next required advisory vote on the frequency of stockholder advisory votes on named executive officer compensation.\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \nCG Oncology, Inc.\n\nDate: June 8, 2026\n \n\n \nBy:\n \n\n/s/ Josh Patterson\n\n \n\n \nName: Josh Patterson\n\n \n\n \nTitle: General Counsel, Chief Compliance Officer and Secretary"}